Zacks Investment Research cut shares of Recordati (OTCMKTS:RCDTF) from a hold rating to a sell rating in a report published on Thursday morning, Zacks.com reports.
According to Zacks, “Recordati S.p.A. is a pharmaceutical company. It engaged in the research, development, manufacturing and marketing of pharmaceuticals for rare disease treatments. The company operates primarily in Russia, Turkey, North Africa and United States of America. Recordati S.p.A. is headquartered in Milan, Italy. “
Shares of OTCMKTS:RCDTF opened at $34.70 on Thursday. Recordati has a one year low of $34.70 and a one year high of $34.87. The firm has a market capitalization of $7.26 billion, a price-to-earnings ratio of 19.83, a PEG ratio of 3.44 and a beta of 0.05.
Recordati Company Profile
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals in Europe, the Middle East, Africa, the United States, Canada, and internationally. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, gynecology and obstetrics, medical devices, musculo-skeletal disorders and analgesia, over the counter/non-prescription pharmaceuticals, urology, allergy, anti-infectives, central nervous system, endocrinology, gastrointestinal, nutrition and related products, immune-suppressants, pain management/inflammation, generics, pneumology, antipyretics and cold preparations, endocrinology, oncology, respiratory, and radio contrast agent, as well as ear, nose, and throat.
Recommended Story: What is a Real Estate Investment Trust (REIT)?
Get a free copy of the Zacks research report on Recordati (RCDTF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recordati Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati and related companies with MarketBeat.com's FREE daily email newsletter.